Immusoft, a Seattle, WA-based gene therapy company, closed the first $3m tranche of its Series B funding round.
The round was led by 600 Mile Challenge Fund. In conjunction with the funding, Dr. Anthony Sun, a prifessional with extensive venture capital experience and board of director roles in multiple biotechnology companies, joined Immusoft’s board.
The company will use the funds to complete its Phase I/II clinical trial in MPS-I (Mucopolysaccharidoses type I) and advance its pipeline, which uses its proprietary Immune System Programming (ISP™) approach to B cell modification for treating diseases.
Led by new CEO and board chairman Sean Ainsworth Immusoft is a gene therapy company which has developed a methodology designed to use a patient’s immune cells to treat disease. Its ISP technology reprograms B cells with the goal of treating diseases, including MPS I, a rare genetic lysosomal storage disease that is expected to be Immusoft’s first clinical application.
ISP, an ex vivo cell culture system that uses a non-viral system to genetically modify B cells, has its origins in a B cell culture system invented by Nobel laureate David Baltimore, Ph.D., which Immusoft has extensively improved upon.